A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy

Trial Profile

A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2018

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Atherosclerosis; Hyperlipoproteinaemia type IIa
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR Wisdom
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 27 Aug 2018 According to an Esperion Therapeutics media release, topline data expected in October 2018
    • 02 Aug 2018 According to an Esperion Therapeutics media release, the company has a Global pivotal phase 3 LDL-C lowering program, consisting of five studies (Study 1, Study 2, Study 3 and Study 4 of bempedoic acid and 053 Study of bempedoic acid / ezetimibe combination pill).
    • 20 Feb 2018 According to an Esperion Therapeutics media release, the company expects the top-line results from this pivotal trial in Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top